J·TEC

FY2026 Q2 (Interim)
Financial Results Briefing Materials

再生医療をあたりまえの医療に

Creating a Future for Regenerative Medicine



Japan Tissue Engineering Co., Ltd. (TSE Growth: 7774)

October 30, 2026

Summary

Maintained profitability in 1H despite recording one-time expenses in Q2.
JACC orders are progressing steadily toward achieving the plan.


FY2026 1H Results

		YoY
Net Sales	1,499	+500
Operating Profit	0	+376
Net Income	4	+375

(Millions of yen)

Sales growth remains solid.
Recorded one-time expenses in Q2.

JACC Orders Received



- Progressed to **210** cases in 1H, the total for this fiscal year is **326** cases (including scheduled in 2H). *1
- Contracts completed with **158** facilities and received orders from **103** facilities (cumulative). *1

*1: Cumulative orders and contracted facilities are as of October 29, 2026.

FY2026 1H Results

- ✓ Achieved revenue growth in all businesses except Teijin Contracts. Significant revenue increase in JACC firmly strengthened our fundamental earning power.
- ✓ The full-year forecast remains unchanged.

(Millions of yen) (rounded down) (percentage changes calculated based on yen units)	FY2025	FY2026			
	1H Actual	1H Actual	YoY Change		Year Forecast Disclosed May 1, 2026
			Amount	Percent	
Regenerative Medicine Product Sales	**633**	**1,144**	**510**	**80%**	**2,070**
Dermatology（JACE、JACEMIN）	381	564	183	48%	1,070
Cartilage（JACC）	203	✓ 522	✓ 319	157%	900
Cornea（NEPIC、OCURAL）	49	57	7	16%	100
Regenerative Medicine Contract Sales	**227**	**215**	**-11**	**-5%**	**640**
General Contracts	106	193	87	81%	430
Teijin Contracts	121	22	-98	-81%	210
LabCyte Business Sales	**137**	**139**	**1**	**1%**	**360**
Total Sales	**998**	**1,499**	**500**	**50%**	**3,070**
Gross Profit	**542**	**967**	**424**	**78%**	**2,000**
SG&A	**918**	**967**	**48**	**5%**	**1,900**
Operating Profit	**-376**	**0**	**376**	**-**	**100**
Ordinary Profit	**-369**	**7**	**376**	**-**	**110**
Net Income	**-371**	**4**	**375**	**-**	**100**

FY2026 1H Results Overview


(Millions of yen)

External Factors	✓JACE(severe burns): Increase in the cancellation rate led to a decrease in orders compared to Q1, but maintaining stable demand. ✓Teijin contracts: Revenue decreased as know-how transfer has run its course.
Internal Factors	✓JACC: **Order volume is steadily increasing. Facility expansion is also progressing on track.** (1H 210 cases acquired, contracted with 158 facilities[*1]) ✓JACEMIN: **Facility expansion / disease awareness succeeded, and orders increased.** ✓In Q2, IT infrastructure temporary costs were recorded (approx. ¥60 million yen, within plan).

*1: As of October 29, 2026.


Quarterly trends

In Q2 (compared to Q1), JACE revenue decrease (-104), but JACEMIN increase (+36) / JACC increase (+22) contributed.



Change in Operating Profit（Year-on-Year）

(Millions of yen)



Regenerative Medicine Products Business: Performance Overview

Dermatology

JACE

In Q2, for severe burns, increase in the cancellation rate led to a decrease in orders compared to Q1, but **maintaining stable demand**. Secured regular orders for other indications.
Working on expanding treatment penetration through the promotion of proper use and information provision activities.

JACEMIN

Orders progressed to **22 cases in 1H, and a cumulative 33 cases**[*1] **for this fiscal year. Concluded an exclusive domestic sales partnership agreement with Maruho Co., Ltd**.
Collaborating to improve recognition and expand treatment facilities in the vitiligo field.

Cartilage

JACC


Orders progressed to **210 cases in 1H, and 326 cases**[*1] for this fiscal year, maintaining strong performance. Contracted with **158 facilities** for OA and received orders from **103 facilities**.
The cultivation of new facilities expecting continuous orders is progressing as planned. Aiming to popularize and expand sales of comprehensive "knee joint preservation therapy" combining regenerative medicine and osteotomy together with OSB. [*2]

Cornea

NEPIC OCURAL

Sales remained solid, primarily at existing facilities. Continuing to cultivate new facilities and raise treatment awareness in collaboration with NIDEK CO., LTD.

*1: Number of orders as of October 29, 2026, including scheduled orders for 2H.
*2: Osferion Biomaterials Corp., an artificial bone manufacturer.



Progress on Growth Strategies: Regenerative Medicine Products Business

JACEMIN: Sales Partnership with Maruho



J-TEC × maruho

Agreed and partnered on a vision to deliver treatment opportunities to all patients who need "JACEMIN".

- For vitiligo, surgical treatment using “JACEMIN” is required for patients for whom existing treatments are insufficiently effective. However, **awareness among medical institutions and patients remains low**.
- Furthermore, as surgical treatments are performed at specialized facilities, **“clinic-hospital collaboration” to smoothly transition patients from their local dermatology clinics to specialized facilities is needed**.
- **By partnering with Maruho, which holds the top domestic market share in medical dermatological topical preparations, we will strengthen information provision to dermatologists nationwide**, expand awareness, and support smooth clinic-hospital collaboration.
- Aiming to establish a treatment system at specialized facilities nationwide to achieve a steady annual volume of over 100 cases within the next few years.

JACC: Sales Partnership with OSB



J-TEC × OSferion Biomaterials

Agreed and partnered on a vision to promote comprehensive "knee joint preservation therapy" combining regenerative medicine and osteotomy.

- OA patients require a comprehensive treatment approach combining "cartilage repair" and "osteotomy[*1]," which corrects joint misalignment and reduces mechanical stress.
- Approximately **13,500 osteotomy procedures** are performed annually. In addition, **60%** of JACC procedures for osteoarthritis are performed in combination with osteotomy.
- **By partnering with Osferion Biomaterials Corp. (OSB),** which holds the top domestic market share in artificial bone and bone grafting materials for osteotomies, **we aim to expand facilities using the “Cartilage Repair + Osteotomy" treatment and strengthen our proposal capabilities toward achieving 1,000 annual cases.**
- **Collaboration started in Q2.**

*1: A surgical procedure that relieves pain by correcting bone alignment and redistributing load through osteotomy, while preserving the patient's own joint.

CDMO Business & LabCyte Business: Performance Overview

CDMO

General

Multiple projects transitioned to the high-value-added Clinical Trial Support Phase and Investigational Product Manufacturing, contributing to revenue growth.

- ActualEyes Inc. — Preparation for domestic Phase III clinical trials started.
- VC Cell Therapy Inc. — Continued CDMO services toward the commercialization of iPS-derived products.
- Metcela Inc. — Concluded a clinical trial product manufacturing contract, and contributing to stable revenue.
- AlliedCel Corp. — Concluded a contract with a view to post-launch manufacturing, and commenced CDMO services.

Teijin

CDMO revenue decreased as know-how transfer has run its course. Planned on the assumption that milestones will be recorded in Q4.

LabCyte

Europe


Established a subsidiary in Germany in October and commenced operations for full-scale deployment via local production, moving forward toward expanding sales. Providing careful follow-up to 8 regular customers, while new customer acquisition activities are also progressing on track.


Japan

Fully commencing approaches to the medical device and materials markets, shifting from the previous cosmetics and chemical products-centric markets.

New Initiative

Completed technology transfer from Osaka University for a research-use intestinal epithelium model, and advancing development toward commercialization.





Progress on Growth Strategies: Regenerative Medicine CDMO Business / LabCyte Business

Strengthening the CDMO Business Portfolio

METCELA

Autologous cell therapy product "JRM-001" for functional single ventricle.

AlliedCel

Induced regulatory T cells "JB-101" for suppressing immune rejection in organ transplant treatments.

ActualEyes

Regenerative medical cell product "AE101" for bullous keratopathy.

CELL THERAPY

Product "MastCT-03" using iPS cells for retinal degenerative diseases.

- In addition **to diversifying the customer base, development pipelines progressed to high-value-added phases**, contributing to revenue growth.
- **Strengthening our unique value proposition as an "Innovation Partner"** more than ever before.
- Presented at BioJapan to showcase initiatives in the field of regenerative medicine.

Establishment of a German Subsidiary for the LabCyte Business Manufacturing Base



Manufacturing Base

Company Name:
Japan Tissue Engineering Europe GmbH
Location: Heidelberg, Germany
Business Description: Development, manufacturing, and sales of LabCyte products
Incorporation Date: October 2026

- **Completed the establishment of the German subsidiary "Japan Tissue Engineering Europe GmbH"** in October.
- **Commenced local activities** aimed at European market expansion. Fully equipped with local facilities.
- Partnering with shared labs to quickly **establish a robust local production and stable supply system.**
- **Aiming to expand market share in Europe,** an advanced market for alternative methods to animal testing.

Progress on Growth Strategies: New Pipeline Area

✓ No changes from the Q1 financial results briefing materials. Development is progressing on track.

Area	Product Name	Indication	Target Launch	Basic Research / Preclinical Trials / Clinical Trials / Regulatory Approval / Insurance Listing
Skin	Allo-JaCE03	Skin defects including burns	FY2027	Approval application completed in Mar 2026
Cancer	JPCAR019	Acute lymphoblastic leukemia	TBD	Phase I/II investigator-initiated clinical trial ongoing, with completion of the Phase I portion expected in FY2026.

Medical Device


Dry allogeneic cultured epidermis　Allo-JaCE03



A new product made from allogeneic cells that can be mass-produced and stocked.

▶ Progressing on track toward approval during this fiscal year.

Autologous CAR-T cells　JPCAR019



Non-viral vectors reduce manufacturing costs.
Expanding treatment options for patients who are not eligible for existing treatments.

▶ Progressing on track toward transition to the Phase II portion during this fiscal year.
Commenced evaluation of business expansion into non-cancer indications.


New Exploration：Started establishing basic technology for "hair follicle organoids" as a new technology exploration for alopecia.

▶ Selected for the "New Aichi Creative Research and Development Subsidy".

Human Capital Management & ESG Initiatives

✓ Formulated a human resources vision for sustainable growth and promoted social contribution activities through regional collaboration.

Formulated "J-TEC Human Capital Vision 2030"



- ✓ Human resources strategy guidelines aimed at enhancing corporate value and sustainable growth.
- ✓ Strengthening three elements based on "Expertise":
  - ✓ Proactive Challenge
  - ✓ High Perspective
  - ✓ Team Co-creation

Hosting a joint exhibition with Takeshima Aquarium



- ✓ First collaboration with Gamagori City Takeshima Aquarium, located in Aichi Prefecture.
- ✓ Through the exhibition, we aim to make the general public feel familiar with "regeneration" and promote proper understanding of regenerative medicine.
- ✓ Original characters drawn by manga artist Hiroyuki Ohashi (born in Gamagori) serve as exhibition guides, creating touchpoints with a wide range of generations.

FY2026 1H Financial Statements Supplementary Information

Operating Profit/Loss by Segment

Regenerative Medical Products Business drives profitability

(Millions of yen) (rounded down)	Operating Profit/Loss			
	FY2025 1H	FY2026 1H	Change Amount	Factors
Product Business	0	405	405	Significant revenue increase from JACC for OA
Contract Business	116	117	1	In-house cultivation is strong, but know-how provision for Teijin CDMO has completed
LabCyte Business	42	23	-19	Strategic investments for overseas expansion
Adjustments	-535	-547	-11	Offset one-time IT infrastructure costs (-60) through Promotion of Efficiency.
Total	-376	0	376	

Investment for Future Growth

(Millions of yen) (rounded down)	FY2025 1H	FY2026 1H	Change Amount
R&D Expenses	268	252	-16
Capital Expenditures (Tangible & Intangible Assets)	6	75	69

Balance Sheet

Strong cash and net assets, maintaining a healthy financial position

(Millions of yen) (rounded down)	March 31, 2026	September 30, 2026	Change Amount
Cash and Deposits	3,250	3,329	79
Other Current Assets	931	975	44
Non-current and Deferred Assets	1,500	1,465	-35
Total Assets	5,682	5,770	87
Current Liabilities	560	644	83
Non-current Liabilities	32	32	-
Total Liabilities	592	676	83
Share Capital	3,997	3,997	-
Capital Surplus	1,827	1,827	-
Retained Earnings	-734	-730	4
Net Assets	5,090	5,094	4
Total Liabilities & Net Assets	5,682	5,770	87

Handling of This Document

This document is provided for informational purposes only and includes forward-looking business plans. It is not intended as an investment solicitation. Any evaluation of our plans or investment decisions should be made at the investor's own discretion.

The Company does not guarantee the achievement or realization of any business targets or projections and assumes no responsibility for them.

All forward-looking statements in this document are based on information available at the time and our current assumptions. Actual results may differ significantly due to changes in economic conditions or other factors affecting the underlying assumptions.

Japan Tissue Engineering Co., Ltd.
〒443-0022 6-209-1 Miyakita-dori, Gamagori City, Aichi Prefecture
TEL: 0533-66-2020 FAX: 0533-66-2019
Email: jtec-info@jpte.co.jp

Reference Materials

Excerpted from “Business Plan and Growth Potential,” disclosed on May 1, 2026.

FY2026 Releases List

Date	Contents
Jun 17, 2026	Selected for the FY2026 "New Aichi Creative Research and Development Subsidy".
Jun 19, 2026	Decision to Establish a Manufacturing and Sales Subsidiary in Germany
Jul 27, 2026	Business alliance for knee joint preservation therapy combining regenerative medicine and osteotomy.
Aug 18, 2026	Selected for the FY2026 Healthcare Industry International Expansion Promotion Project Subsidy ✓ **Subsidy for overseas expansion of the product business, focusing on Taiwan**, which has medical needs for severe burns, etc.
Sep 24, 2026	Joint exhibition with Takeshima Aquarium "Is the hooked fish okay? Exhibition".
Oct 28, 2026	J-TEC and Maruho conclude a sales partnership agreement for the autologous cultured epidermis "JACEMIN".

Glossary of Our Products

Regenerative Medicine Products Business

We provide products cultured from the patient's own cells under insurance coverage.

NEPIC / OCURAL

Autologous Cultured Corneal Epithelium
Autologous Cultured Oral Mucosal Epithelium

■ Limbal Stem Cell Deficiency（LSCD）

JACE

Autologous Cultured Epidermis

■Severe burns ■Epidermolysis bullosa
■Giant congenital melanocytic nevus

JACEMIN


Autologous Cultured Epidermis Containing Melanocytes

■Vitiligo vulgaris.

JACC

Autologous Cultured Cartilage

■ Osteoarthritis of the knee（OA） ■ Traumatic cartilage defect / Osteochondritis dissecans




LabCyte Business

We sell kits to verify the safety of products like cosmetics and drugs using human cells as an alternative to animal testing

LabCyte

Human Cultured Tissue for Research

■Epidermis models
■Corneal epithelium models



EpiSensA

Skin Sensitization Test Method to evaluate the potential for substances to cause skin allergies, compliant with OECD guidelines

Our History

Leveraging a quarter century of experience in launching five products, we have established a unique platform for autologous cell therapies, distinct from traditional pharmaceuticals

Company Name	Japan Tissue Engineering Co., Ltd.（J-TEC）
Headquarters	Gamagori City, Aichi Prefecture
Representative Director	President and CEO: Kazuto Yamada
Established	February 1st, 1999
Share Capital	3,997,670,000 yen
Employees	200（As of March 31, 2026）
Business Areas	1. Regenerative Medicine Product Business 2. Regenerative Medicine Contract Business 3. LabCyte Business
Major Shareholders	Teijin Limited（57.7%） NIDEK Co., Ltd.（10.4%）

- 1999 Established
- 2007 Listed on JASDAQ Securities Exchange NEO (Currently Tokyo Stock Exchange Growth Market)
- 2009 Insurance Approval for JACE (severe burns)
- 2013 Insurance Approval for JACC (traumatic indications)
- 2016 Insurance Approval for JACE (Nevi)
- 2019 Insurance Approval for JACE (Epidermolysis Bullosa)
- 2020 Insurance Approval for NEPIC
- 2021 Insurance Approval for OCURAL
- 2024 Insurance Approval for JACEMIN
- 2026 Insurance Approval for JACC (Knee Osteoarthritis)

Social Implementation Phase

Our Growth Foundation

As Japan's first regenerative medicine platform company, we strive to establish a stable revenue foundation and drive rapid growth

【Achievements】Japan's first Regenerative Medicine Platformer

Founded in 1999, leading Japan's regenerative medicine industry for over 25 years.

5


5 products approved-Global track record

3,700+

3,700+ patients treated and a strong physician network

【Foundation】Strong Three-Pillar Business Model

Source of manufacturing and sales expertise



Advancing animal testing alternatives through global expansion of human cultured tissues

Expert support backed by launch experience

【Growth】Growth drivers for reaching ¥5B in revenue



Reimbursed JACC for knee osteoarthritis (target: ¥3B revenue)




Completed regulatory filing for manufacturing and marketing approval of dried allogeneic cultured epidermis Allo-JaCE03

Regenerative Medicine Product Business: Market Potential of "JACC"

Competitive Advantage

- ✓ A **unique, potentially curative approach distinct from conservative therapy** (exercise/drugs) and joint replacement
  (Cartilage has very limited natural healing once damaged)
- ✓ **No products with the same mechanism currently**
- ✓ 10+ years of real-world use data
- ✓ **Proven efficacy and safety** from clinical trials



Pre-transplant | 6 months post-transplant | 1 year post-transplant

Clinical trial results: 97.4% showed repair

Market Potential

- ✓ Target common diseases to boost awareness of regenerative medicine through insurance coverage

Symptomatic OA	Approx. 10M	
Eligible Population	Approx. 10K cases/year	*Estimated based on surgical volume and product indication criteria
Initial Target	Approx. 1,000 cases/year	

Insurance coverage criteria for "JACC"

Patients diagnosed with OA

Not improved with conservative therapy (exercise/medication)

Cartilage defect area ≥ 2 cm^2 * And a sufficient amount of normal cartilage remains

Regenerative Medicine Product Business: Product Lineup

	Autologous Cultured Epidermis	Autologous Cultured Cartilage	Autologous Cultured Corneal Epithelium	Autologous Cultured Oral Mucosal Epithelium	Autologous Cultured Epidermis Containing Melanocytes
Product	ジェイス® 自家培養表皮 	ジャック® 自家培養軟骨 	ネピック® 自家培養角膜上皮 	オキュラル® 自家培養口腔粘膜上皮 	ジャスミン メラノサイト含有自家培養表皮 
	Japan's First Regenerative Medicine Product	Japan's 2nd Regenerative medicine product	First Regenerative Medicine Product in Japan for Corneal Field	2nd Regenerative Medicine Product in Japan for Corneal Field	Regenerative Medicine Product for Vitiligo with a large patient population
Approval Insurance	Oct. 2007 Jan. 2009	①Jul. 2012 ②May 2025 ①Apr. 2013 **②Jan. 2026**	Mar. 2020 Jun. 2020	Jun. 2021 Dec. 2021	Mar. 2023 Oct. 2024
Indications	①Severe Burns ②Congenital giant pigmented nevus ③Epidermolysis bullosa	① Cartilage defects or osteochondritis of the knee ② **Osteoarthritis**	Limbal stem cell deficiency	Limbal stem cell deficiency	Intractable Vitiligo unresponsive to non-surgical treatment
Insurance Price	Tissue Transport Set 4,460,000 yen Processing/Transplant kit 154,000 yen / per sheet	Tissue Transport Set 1,000,000 yen Processing/Transplant kit 1,890,000 yen	Tissue Transport Set 4,280,000 yen Processing/Transplant kit 5,470,000 yen	Tissue Transport Set 4,280,000 yen Processing/Transplant kit 5,470,000 yen	Tissue Transport Set 4,460,000 yen Processing/Transplant kit 154,000 yen / per sheet
Technology Origin	Harvard University Professor Howard Green	Hiroshima University Professor Mitsuo Ochi	University of Modena Professor G Pellegrini Professor M De Luca	Osaka University Professor Koji Nishida	University of Modena Professor G Pellegrini Professor M De Luca

Regenerative Medicine Contract Business Model

✓ As an innovation partner in regenerative medicine, we support end-to-end product development from customer seeds.

Value built by J-TEC

Development Expertise **Regulatory Capability**

Track Record in Commercialization and Manufacturing

Network and Trust **Full range of in-house functions**



Customer Relations

Clinical settings Collaboration

TEIJIN Collaboration

Building systems to deliver products together with partners


Cumulative Commissioned projects 296 cases

Items	cases
Product development support Tech transfer, test cultures, preclinical studies, analytical validation, and SOP/document preparation	121
Regulatory affairs support PMDA consultations (pre-meetings & formal advice) and compliance with the Act on Safety of Regenerative Medicine, etc	30
Manufacturing & Testing support Investigational products and cell-processed materials	42
Clinical development support Protocol outlines, statistical analysis, data management, and clinical study reports	28
Facility & equipment support Consulting on the design and operation of manufacturing facilities	7
Others Sales support, equipment setup, and cell storage	68

LabCyte Business Model

- ✓ Advanced culture tech applied to offer “LabCyte Series” human tissues for research
- ✓ 3D human tissues for topical drugs, cosmetics, and skin/cornea research

Product Delivery Process



Manufacturers and research institutions handling chemicals
(e.g., daily necessities, pharma, cosmetics, chemical products)




Use LabCyte for R&D


~~Animal Testing~~

	LabCyte EPI-MODEL	LabCyte EPI-KIT	LabCyte Corneal Model
Product	3D Cultured Human Epidermis	Human Epidermis Model Kit	3D Cultured Human Corneal Epithelium
			
OECD Test Guidelines	Skin Irritation test (TG439) Skin Corrosion test (TG431) Skin Sensitization test (TG442D)	–	Eye Irritation test (TG492)
ISO (Medical Devices)	Skin Irritation test (ISO10993-23)		–
Launch Date	March 2005	April 2013	July 2010

Autologous Cultured Epidermis “JACE”






Indications	① Severe Burns Indicated for burns where deep second- and third-degree areas **total ≥30% total body surface area (TBSA)** ② Congenital Giant Pigmented Nevus Indicated for nevi **≥5% TBSA** or when standard treatments cannot adequately remove the lesion ③ Epidermolysis bullosa dystrophica and junctional epidermolysis bullosa Indicated for erosions/ulcers persisting **~4 weeks or recurrent ulceration** with repeated epithelialization
Insurance reimbursement price	・Tissue Transport Set: 4,460,000 yen ・Processing/Transplant kit: 154,000 yen per sheet ※ Eligible for high-cost medical expense coverage Limits:（Severe burns）**40 sheets** ※if medically necessary, up to **50 sheets** （nevi）**30 sheets** （epidermolysis bullosa）**50 sheets**
Technology	Originated from Professor Howard Green of Harvard University
Facility Standards	Severe burns: limited to facilities meeting required standards No specific facility standards for giant congenital nevi or epidermolysis bullosa
Healing timeline	Manufacturing and culture period: approximately 3 weeks from tissue collection to delivery Product shelf life: 56 hours Engraftment period: engraftment occurs within 1 week, with the epidermis stabilizing in approximately 1 month
Process	

Autologous Cultured Epidermis Containing Melanocytes “JACEMIN”







Indications	① Vitiligo* ・Vitiligo patients ≥12 years old unresponsive to or unsuitable for topical or light therapy. ・**Symptoms remain stable (unchanged) for about 12 months**
Insurance reimbursement price	・Tissue Transport Set: 4,460,000 yen ・Cultured Epidermis Package: 154,000 yen per sheet ※ Covered by the High-Cost Medical Expense Benefit system; out-of-pocket cost for an average-income person is about ¥220,000 (varies by income)
Technology	Originated from Professors G Pellegrini and M De Luca of the University of Modena (Italy)
Facility Standards	A full-time physician with experience performing **at least three skin graft procedures**, or a full-time physician who performs such surgeries under the supervision of an experienced doctor
Healing timeline	**Manufacturing & culture period:** About 5 weeks from tissue collection to delivery **Product shelf life:** 60 hours **Engraftment period:** Engrafts in about 1 week; epidermis stabilizes in ~1 month
Process	

* Complete depigmented patches due to vitiligo, Vogt–Koyanagi–Harada disease, chemical causes or congenital conditions such as piebaldism

Autologous Cultured Cartilage “JACC”





Indications	①Traumatic cartilage defect or osteochondritis dissecans. However, it is limited to cases where no other treatment options are available, and the cartilage defect area is 4cm² or larger. ②Osteoarthritis of the knee However, this is limited to cases where clinical symptoms do not improve through conservative treatments such as exercise therapy, and cartilage defect area is 2cm² or larger
Insurance reimbursement price	・Tissue Transport Set: 1,000,000 yen ・Processing/Transplant Kit: 1,890,000 yen Regardless of the number of units used ※ Covered by the High-Cost Medical Expense Benefit system; out-of-pocket cost for an average-income person is about ¥250,000 (varies by income)
Technology	Originated from Professor Mitsuo Ochi of Hiroshima University
Facility Standards	A university hospital or other teaching/research institution, or a facility that performs at least 100 knee surgeries per year
Healing timeline	**Manufacturing & culture period:** About 4 weeks from cartilage tissue harvest to delivery **Product shelf life:** 80 hours **Engraftment period:** Use crutches or a brace (non-weight-bearing) for about 4 weeks post-op until the repair tissue stabilizes
Process	

Autologous Cultured Corneal Epithelium “NEPIC”
Autologous Cultured Oral Mucosal Epithelium “OCURAL”








Seller: NIDEK Co., Ltd.

Indications	Limbal Stem Cell Deficiency (LSCD)*
Insurance reimbursement price	・Tissue Transport Set: 4,280,000 yen ・Cultured Corneal Epithelium Package: 5,470,000 yen ※ Eligible for high-cost medical expense coverage
Technology	NEPIC Originated from Professors G Pellegrini and M De Luca of the University of Modena (Italy) OCURAL Originated from Professor Koji Nishida of Osaka University
Facility Standards	The facility must have a full-time physician with experience performing corneal transplantation
Healing timeline	**Manufacturing & culture period:** About 4 weeks from tissue collection to delivery **Product shelf life:** 60 hours **Engraftment period:** Engrafts in in about 12 weeks; ocular surface stabilizes in 6–12 months
Process	Patients ← Transplantation NEPIC Harvesting of corneal limbal tissue → Enzymatic treatment → Seeding onto 3T3-J2 cells for cell expansion → Isolation of cells → Culturing → Sheet formation → Sheet detachment OCURAL Harvesting of oral mucosal tissue



*Candidates for NEPIC exclude patients with congenital corneal epithelial stem cell deficiency (such as Stevens-Johnson syndrome, ocular cicatricial pemphigoid, graft-versus-host disease, and aniridia), recurrent pterygium, and idiopathic corneal epithelial stem cell deficiency.